Market research
0ET.F Esperion Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 698M
- P/E ratio
- 0.0
- Analyst target
- 42.45
- Dividend yield
- Not available
- Beta
- 1.06
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US29664W1053
- Market cap
- 698M
- P/E ratio
- 0.0
- Analyst target
- 42.45
- Dividend yield
- Not available
- Beta
- 1.06
About
About Esperion Therapeutics, Inc
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. As of July 13, 2026, Esperion Therapeutics, Inc. was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0ET.F discussion.
5 years, 4 months ago
Esperion Therapeutics, Inc is currently in a long term downtrend where the price is trading 30.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
Esperion Therapeutics, Inc's total revenue rose by 881.5% to $10M since the same quarter in the previous year.
Its net income has dropped by 68.7% to $-104M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.0% to $-69M since the same quarter in the previous year.
Based on the above factors, Esperion Therapeutics, Inc gets an overall score of 2/5.